Long-term safety and efficacy study of adapalene 0.3% gel

Journal of Drugs in Dermatology

Volumn 7, Issue 6, 2008, Pages

  Weiss, Jonathan S ^a   Thiboutot, Diane M ^b   Hwa, Joyce ^c   Liu, Yin ^c   Graeber, Michael ^c  

^a Gwinnett Dermatology   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c Galderma Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; DERMATOLOGICAL AGENT; NAPHTHALENE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHEMA; FEMALE; GEL; HUMAN; MALE; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN;

ADOLESCENT; ADULT; CHILD; DERMATOLOGIC AGENTS; ERYTHEMA; FEMALE; GELS; HUMANS; MALE; NAPHTHALENES; SKIN;

EID: 52449091932     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Weiss JS, Shavin JS. Topical retinoid and antibiotic combination therapy for acne management. J Drugs Dermatol. 2004;3:146-154.
2. Bergfeld WF. The evaluation and management of acne: economic considerations. J Am Acad Dermatol. 1995;32:S52-S56.
3. Koo J. The psychosocial impact of acne: patients' perceptions. J Am Acad Dermatol. 1995;32:S26-S30.
4. Webster GF. Acne vulgaris. BMJ. 2002;325:475-479.
5. Webster G. Mechanism-based treatment of acne vulgaris: the value of combination therapy. J Drugs Dermatol. 2005;4:281-288.
6. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49 (suppl):S1-S37. (Pubitemid 36791495)
7. Waugh J, Noble S, Scott LJ. Adapalene: a review of its use in the treatment of acne vulgaris. Drugs. 2004;64:1465-1478. (Pubitemid 38980458)
8. Chivot M. Retinoid therapy for acne. a comparative review. Am J Clin Dermatol. 2005;6:13-19. (Pubitemid 40289257)
9. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004;292:726-735. (Pubitemid 39062528)
10. Leyden JJ, Shalita A, Thiboutot D, et al. Topical retinoids in inflammatory acne: a retrospective, investigator-blinded, vehiclecontrolled, photographic assessment. Clin Ther. 2005;27:216-224. (Pubitemid 40462015)
11. Hensby C, Cavey D, Bouclier M, et al. The in vivo and in vitro anti-inflammatory activity of cd271: a new retinoid-like modulator of cell differentiation. Agents Actions. 1990;29:56-58. (Pubitemid 20091843)
12. Tenaud I, Khammari A, Dreno B. In vitro modulation of tlr-2, cd1d and il-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol. 2007;16:500-506.
13. Bikowski JB.Mechanisms of the comedolytic and antiinflammatory properties of topical retinoids. J Drugs Dermatol. 2005;4:41-47.
14. Russell JJ. Topical therapy for acne. Am Fam Phys. 2000;61:357-366. (Pubitemid 30067471)
15. Feldman S, Careccia RE, Barham KL, et al. Diagnosis and treatment of acne. Am Fam Phys. 2004;69:2123-2130.
16. Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: A meta-analysis of five randomized trials. Br J Dermatol. 1998;139 (suppl):48-56.
17. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tretinoin microsphere 0.04% and 0.1%. Cutis. 2005;75:238-243. (Pubitemid 40627632)
18. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1%. Cutis. 2005;75:289-293. (Pubitemid 40826409)
19. Greenspan A, Loesche C, Vendetti N, et al. Cumulative irritation comparison of adapalene gel and solution with 2 tazarotene gels and 3 tretinoin formulations. Cutis. 2003;72:76-81. (Pubitemid 37229762)
20. Dunlap FE, Mills OH, Tuley MR, et al. Adapalene 0.1% gel for the treatment of acne vulgaris: Its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol. 1998;139 (suppl):17-22.
21. Pariser DM, Thiboutot DM, Clark SD, et al. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: a randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis. 2005;76:145-151. (Pubitemid 41290901)
22. Thiboutot D, Pariser DM, Egan N, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double- blind, controlled, phase iii trial. J Am Acad Dermatol. 2006; 54:242-250. (Pubitemid 43144393)
23. Thiboutot DM, Gollnick HP. Treatment considerations for inflammatory acne: Clinical evidence for adapalene 0.1%in combination therapies. J Drugs Dermatol. 2006;5:785-794.
24. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651-663. (Pubitemid 46400177)